GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medigene AG (FRA:MDG1) » Definitions » Additional Paid-In Capital

Medigene AG (FRA:MDG1) Additional Paid-In Capital : €480.25 Mil(As of Dec. 2023)


View and export this data going back to 2000. Start your Free Trial

What is Medigene AG Additional Paid-In Capital?


Medigene AG's quarterly additional paid-in capital increased from Dec. 2022 (€479.94 Mil) to Jun. 2023 (€480.11 Mil) and increased from Jun. 2023 (€480.11 Mil) to Dec. 2023 (€480.25 Mil).

Medigene AG's annual additional paid-in capital increased from Dec. 2021 (€479.59 Mil) to Dec. 2022 (€479.94 Mil) and increased from Dec. 2022 (€479.94 Mil) to Dec. 2023 (€480.25 Mil).

Medigene AG Additional Paid-In Capital Historical Data

The historical data trend for Medigene AG's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medigene AG Additional Paid-In Capital Chart

Medigene AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 478.28 478.94 479.59 479.94 480.25

Medigene AG Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 479.59 479.76 479.94 480.11 480.25

Medigene AG Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Medigene AG Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Medigene AG's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Medigene AG (FRA:MDG1) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medigene AG (FRA:MDG1) » Definitions » Additional Paid-In Capital
Comparable Companies
XTER:T5O XTER:HPHA OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX ALNY OCSE:GMAB BGNE BMRN INCY TECH UTHR RPRX
Traded in Other Exchanges
0QGJ:UK MDG1:Germany MDG1:Austria
Address
Lochhamer Strasse 11, Martinsried, Planegg, BY, DEU, 82152
Website
https://www.medigene.com
Medigene AG is an immuno-oncology biotechnology company. focused on developing differentiated T Cell Receptor engineered T cell (TCR-T) therapies for the treatment of multiple solid tumor indications with a high unmet medical need. The operating segments of the organization are Immunotherapies and Other products. Immunotherapies consist of T-cell receptor-based adoptive T-cell therapy and DC vaccines. The group operates in the United States, Germany, and Asia, of which the majority of the revenue is derived from operations in Germany.

Medigene AG (FRA:MDG1) Headlines

No Headlines